IGF1 and cancer: Factors such as hyperinsulinemia, hyperglycemia, visceral adiposity, estrogen signaling, and IGF-1 pathways, alongside active inflammation, could trigger carcinogenesis and cancer progression, potentially explaining the MetS–EAC link [36].